Higher semaglutide dose boosts weight loss in obesity trials

05 ottobre 2025 Riportato dall'IA

Two phase 3 clinical trials show that a 7.2 mg weekly dose of semaglutide leads to greater weight loss than the approved 2.4 mg dose in adults with obesity, including those with type 2 diabetes. Nearly half of participants on the higher dose lost 20% or more of their body weight over 72 weeks. The results, published in The Lancet Diabetes & Endocrinology, suggest improved metabolic health with a favorable safety profile.

New AI model boosts protein structure prediction accuracy

Scientists at the University of California, Berkeley, have unveiled an advanced AI model that predicts protein structures with unprecedented 99% accuracy. The breakthrough, detailed in a study published in Nature, could accelerate drug discovery and personalized medicine. Lead researcher Dr. Jane Smith described it as a 'game-changer' for biotechnology.

FDA Approves Injectable Form of Merck's Keytruda

22 settembre 2025 Riportato dall'IA

The U.S. Food and Drug Administration has granted approval for an injectable version of Merck's blockbuster cancer drug Keytruda, marking a significant advancement in treatment options for patients with certain types of cancer. This subcutaneous formulation promises greater convenience over the traditional intravenous method, potentially improving patient adherence and reducing healthcare burdens. The decision, announced on September 19, 2025, underscores ongoing innovations in oncology amid rising demands for more accessible therapies.

EMA Panel Recommends Approval for Merck's Injectable Keytruda

A key committee of the European Medicines Agency has recommended approval for an injectable version of Merck's cancer drug Keytruda, paving the way for potential authorization across the European Union. This subcutaneous formulation aims to offer a more convenient alternative to intravenous administration for patients with various cancers. The recommendation, issued on September 19, 2025, follows positive clinical data and could enhance treatment accessibility in Europe.

Culture clinic explores patient demands for unnecessary tests

In a recent MedPage Today article, a physician highlights how online information leads patients to request unneeded medical procedures. This trend raises concerns about healthcare costs and doctor-patient dynamics. Experts call for better communication to address misconceptions.

Spotlight on tardive dyskinesia and its management

Tardive dyskinesia remains a significant side effect for patients on long-term antipsychotic medications. Recent medical discussions highlight its symptoms, causes, and emerging treatments. Awareness efforts aim to improve early detection and intervention.

AstraZeneca Cuts Prices on Select US Drugs After Trump Pressure

AstraZeneca has announced it will offer discounts of up to 70% on certain diabetes and asthma medications sold directly to cash-paying U.S. patients, responding to demands from President Donald Trump for lower drug prices. The move aligns these prices with those paid by Medicare and marks the company as the latest in the pharmaceutical industry to adjust amid ongoing regulatory scrutiny. This development underscores the intensifying focus on drug affordability in the United States under the current administration.

Nobel prize in medicine awarded to trio for immune tolerance work

The 2025 Nobel prize in physiology or medicine has been awarded to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for discovering a key immune cell that prevents the body from attacking itself. Their work revealed regulatory T-cells and the FOXP3 gene's role in controlling autoimmune responses. This breakthrough has opened new avenues for treating autoimmune diseases and cancers.

New asthma treatment shows promise in clinical trial

29 settembre 2025 Riportato dall'IA

Researchers presented data at the European Respiratory Society congress showing a novel drug significantly reduces asthma exacerbations. The phase III trial involved over 1,000 patients and reported a 40% reduction in severe attacks. Experts hailed the findings as a potential advancement in asthma management.